Product Information
LAMIVUDINE-ZIDOVUDINE TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.7351 per EA under NDC 31722050660. Its NADAC has been published 524 times since Aug 10, 2016.
FDA first approved this application on Sep 17, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150; 300 mg/1; mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722050660
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
LAMIVUDINE; ZIDOVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA079124FDA Approved
9/17/2015
TE Code
AB
On Market Since
9/18/2015
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has been published 524 times since Aug 10, 2016, and over the history we have for it it has declined 66.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7351 per EA |
|---|---|
| All-time high | $2.6615 (Sep 14, 2016) |
| All-time low | $0.5570 (Jan 21, 2026) |
| 52-week high | $0.7351 |
| 52-week low | $0.5570 |
| Median price | $0.9217 |
| Average price | $1.0249 |
| Largest weekly change | +57.7% (Aug 21, 2019) |
| Weeks tracked | 524 |
| Tracking since | Aug 10, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LAMIVUDINE and ZIDOVUDINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LAMIVUDINE-ZIDOVUDINE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE-ZIDOVUDINE TABLET, manufactured by Camber Pharmaceuticals Inc., is $0.7351 per EA (NDC 31722050660), effective Aug 19, 2026.
How has the price of LAMIVUDINE-ZIDOVUDINE TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has declined 66.3%. It has been tracked across 524 weekly CMS publications since Aug 10, 2016.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE-ZIDOVUDINE TABLET?
Since Aug 10, 2016, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has ranged from a low of $0.5570 (Jan 21, 2026) to a high of $2.6615 (Sep 14, 2016), with a median of $0.9217 per EA.
Are there cheaper alternatives to LAMIVUDINE-ZIDOVUDINE TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LAMIVUDINE-ZIDOVUDINE TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LAMIVUDINE-ZIDOVUDINE TABLET?
LAMIVUDINE-ZIDOVUDINE TABLET (NDC 31722050660) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.